Your browser version may not work well with NCBI's Web applications. More information here...
1: Pharm Res. 2009 Jan;26(1):218-23. Epub 2008 Sep 12.Click here to read Links

Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model.

Mittal G, Chandraiah G, Ramarao P, Ravi Kumar MN.

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.

PURPOSE: It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-beta estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition. MATERIALS AND METHODS: Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model. RESULTS: The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally. CONCLUSION: Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.

PMID: 18787933 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Estrogen (Cenestin® , Enjuvia® , Estrace® , ...)

    Estrogen is used to treat hot flushes ('hot flashes'; sudden strong feelings of heat and sweating) in women who are experiencing menopause ('change of life', the end of monthly menstrual periods). Some brands of estrogen...

  • Source: AHFS Consumer Medication Information